Trial Profile
Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Pharmacodynamics
- 06 Mar 2018 Status changed from recruiting to completed.
- 02 Nov 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 06 Jan 2015 New trial record